ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1815

Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis

yan li1, Kunpeng Li1, Zheng Zhao1, yanyan wang1, Jingyu Jin1, jianglin zhang1, Jian Zhu1 and feng huang2, 1First Medical Center, General Hospital of Chinese People's Liberation Army, Beijing, China (People's Republic), 2Chinese PLA General Hospital, Beijing, China (People's Republic)

Meeting: ACR Convergence 2021

Keywords: Efficacy, Iguratimod, Safety, spondyloarthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Iguratimod, also known as T-614, is a new type of small molecule compound with anti-inflammatory and immunomodulatory effects; It was listed in China(2011) and Japan(2012) for the treatment of rheumatoid arthritis;its safety and effectiveness have been verified in patients with rheumatoid arthritis. As Iguratimod could inhibit the production of inflammatory cytokines, such as IL-1 and TNF; block the IL-17 signalling pathway and inhibit cyclooxygenase, Iguratimod may be effective in the treatment of SPA/AS. However, no rigorous clinical research exists to confirm this speculation. Therefore, this study aimed to evaluate the efficacy and safety of Iguratimod in patients with active SpA.

Methods: Subjects with active SpA were enrolled and randomly divided into two groups at a ratio of 1:2 (placebo vs. Iguratimod). On the basis of non-steroidal anti-inflammatory drugs, combined treatment with Iguratimod or placebo, followed by follow-up every 4 weeks for 24 weeks. The primary efficacy endpoint was to evaluate the alleviation rate of ASAS20; the important improvement of ASDAS and the efficacy of spinal mobility, physical function and quality of life at the 24th week.

Results: A total of 48 cases in the Iguratimod group and 25 cases in the placebo group were included in the final analysis. On the 24th week, the percentage of responders to ASAS20 (80% vs. 44%) and ASAS40 (56% vs. 20%) treated with Iguratimod were significantly higher than that in the placebo group (P < 0.05). Twelve cases had gastrointestinal discomfort, of which eight were in the Iguratimod group (16.7%, one case withdrew from the study due to diarrhoea) and four were in the placebo group (16.0%). No significant difference was found between the two groups (P < 0.05). Three cases of elevated transaminase were observed in the Iguratimod group and none in the placebo group, with no significant difference (P < 0.05).

Conclusion: Iguratimod could significantly reduce the symptoms and signs of patients with active SpA. It could improve the physical function and quality of life of these patients and the overall safety and tolerance are good.


Disclosures: y. li, None; K. Li, None; Z. Zhao, None; y. wang, None; J. Jin, None; j. zhang, None; J. Zhu, None; f. huang, None.

To cite this abstract in AMA style:

li y, Li K, Zhao Z, wang y, Jin J, zhang j, Zhu J, huang f. Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10). https://acrabstracts.org/abstract/randomised-double-blind-placebo-controlled-study-of-iguratimod-in-the-treatment-of-active-spondyloarthritis/. Accessed August 8, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/randomised-double-blind-placebo-controlled-study-of-iguratimod-in-the-treatment-of-active-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies